Navigation Links
PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
Date:6/23/2008

BOSTON, June 23 /PRNewswire-FirstCall/ -- According to new data from PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services organization, the number of new industry-sponsored clinical trial initiations, or starts, surged another 12 percent to a record high in 2007. PAREXEL's analysis shows that the biopharmaceutical industry submitted 662 commercial Investigational New Drug (IND) applications in support of new clinical studies for drugs in 2007, up from the previous record of 593 in 2006.

"The number of commercial IND submissions is a key measure of the number of clinical studies that are initiated by biopharmaceutical companies. IND submissions have been steadily increasing from 2004 to 2007, from 542 to 662 submissions, representing a 22 percent increase over this three year time period," said Mark Mathieu, Director of Publications at PAREXEL and Editor of PAREXEL's Bio/Pharmaceutical R&D Statistical Sourcebook, 2008/2009.

Mr. Mathieu observed, "There has been a less consistent year-over-year pattern for commercial IND submissions of therapeutic biological products as compared with IND submissions related to drug products. PAREXEL data show that 83 commercial INDs were submitted for therapeutic biological products in 2007, which was down 27 percent from 114 submitted in 2006. The 114 INDs submitted in 2006 however, represented a 67 percent increase over submissions in 2005."

Oncology Studies Represent Largest Percentage of New Clinical Studies

According to PAREXEL data, new clinical studies of oncology drugs, which rose another 13 percent in 2007, comprised the largest percentage among all therapeutic areas for new clinical trial starts in 2007-nearly 15 percent of the t
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PAREXEL Expands Global Clinical Pharmacology Capabilities
2. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
3. Stroke Study Reveals a Key Target For Improving Treatment
4. As Summer Heats Up, New Survey Reveals Need for Effective Sweat Treatments
5. Nationwide Progress Poll Reveals Increased Efforts by Hospitals to Control MRSA Infection
6. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
7. Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R)
8. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
9. Adding Breast Ultrasound Screening to Mammography Reveals Cancers not Seen on Mammography Alone in Women at Increased Risk for Breast Cancer
10. Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals
11. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 Depomed, Inc. (Nasdaq: ... offer, subject to market and other conditions, $230 million ... (the "Notes"). Depomed, Inc. ("Depomed") expects to grant the ... up to an additional $34.5 million aggregate principal amount ... RBC Capital Markets, LLC will act as joint book-running ...
(Date:9/2/2014)... signs monitoring devices market with over 40% market share, ... American and European vital signs monitors markets is expected ... the end of 2013. They have been driving the ... people across these economies. The European market is expected ... rising demand for home health patient monitoring devices due ...
(Date:9/2/2014)... YORK , Sept. 2, 2014 ... is available in its catalogue: Acute ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... 2014 Summary GlobalData,s clinical trial ... H2, 2014" provides data on the Acute Heart ...
Breaking Medicine Technology:Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 2Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 3Market of Vital Signs Monitoring Devices Forecast to 2018 2Market of Vital Signs Monitoring Devices Forecast to 2018 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... 2007 - Lux Biosciences,Inc., a privately held biotechnology ... today that the company's,next-generation calcineurin inhibitor, LX211, is ... Research in Vision and,Ophthalmology (ARVO) annual meeting, being ... an oral presentation being given on May 5 ...
... at 59th American Academy of Neurology Annual Meeting, ... /PRNewswire/ --,PTC Therapeutics, Inc. (PTC), a biopharmaceutical company ... targeting,post-transcriptional control processes, today announced positive,interim data from ... patients,with Duchenne muscular dystrophy (DMD) due to a ...
Cached Medicine Technology:Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 2Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 3Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 4PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 4PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 5
(Date:9/3/2014)... September 03, 2014 An inspiring story ... be documented in the season finale of “Extreme Weight ... and his teenage daughter from Highlands Ranch, Colo. who ... she weighs 265 pounds. Their challenge is to team ... Featuring a unique, non-competitive approach to weight loss transformations, ...
(Date:9/3/2014)... Gorda, FL (PRWEB) September 03, 2014 ... healthcare delivery, increases patient safety, decreases medical errors, ... providers. , To mark the important role ... in America, IHS and others across the U.S. ... Technology (NHIT) Week , September 16-20, 2014. With ...
(Date:9/3/2014)... 2014 Independent review is a ... evidence-based health care along the continuum. Health plans, ... expertise of accredited independent review organizations (IROs) at ... , As a core function, IROs provide objective, ... of medical necessity. Yet backed by expertise, they ...
(Date:9/2/2014)... IA (PRWEB) September 03, 2014 IMCA ... will kick off on September 1, 2014 at the ... 6, the pre-race ceremony will include a check presentation ... For The Warriors® is a national nonprofit organization that ... the fallen who have sustained physical and psychological wounds ...
(Date:9/2/2014)... concentrated pot might be risky business for women, ... The study is the first to demonstrate sex ... , Psychology professor Rebecca Craft showed that, ... at least 30 percent more sensitive than males ... ingredient in cannabis. Females also develop tolerance to ...
Breaking Medicine News(10 mins):Health News:“Extreme Weight Loss”: Jeff and Juliana’s Journey begin at the University of Colorado Anschutz Health and Wellness Center 2Health News:Innovative Healthcare Solutions (IHS) Celebrates National Health IT Week September, 15-19, 2014 2Health News:Independent Review Expands Its Scope: Case Studies in Context 2Health News:Independent Review Expands Its Scope: Case Studies in Context 3Health News:IMCA to Present Donation to Hope For The Warriors 2Health News:Estrogen increases cannabis sensitivity 2Health News:Estrogen increases cannabis sensitivity 3
... is a statement by ADA President John S. ... (D-Mich.) and Candice Miller (R-Mich.) for introducing the ... that would bolster America,s capacity to respond to ... of the extensive education, training and professionalism of ...
... can divide into two, first it must duplicate its genetic ... of chromosomes then have to be separated from one another ... both daughter cells are genetically identical to the original, or ... called the centrosome, and a copy of the centrosome, position ...
... ONTARIO, CANADA Canada may not be able to ... brain drain of the mid-90s as a result of ... CMAJ published online today http://www.cmaj.ca/cgi/rapidpdf/cmaj.090209 . Health ... the public and government understand the impact of the ...
... (NYSE: RMD ) today announced record revenue and ... the December 2008 quarter was $223.0 million, a 10% increase ... quarter ended December 31, 2007. For the quarter ended ... net income was $33.9 million, an increase of 18% and ...
... study says , , THURSDAY, Feb. 5 (HealthDay News) -- Nearly ... that could lead to paralysis or death, but greater use ... a new study finds. , "Wearing a seat belt is ... against potentially devastating injury," said lead researcher Dr. Marjorie C. ...
... Feb. 5 A coalition of concerned consumer advocate ... Medical Consumers, called on the New York State Legislature ... pharmaceutical company gifts to doctors. This ban would exclude ... focus on gifts valued at over fifty dollars. Pharmaceutical ...
Cached Medicine News:Health News:Statement by ADA President John S. Findley on the Dental Emergency Responder Act Introduced Today by Reps. Stupak and Miller 2Health News:CSHL scientists discover link between control of chromosome duplication and segregation 2Health News:CSHL scientists discover link between control of chromosome duplication and segregation 3Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 2Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 3Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 4Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 5Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 6Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 7Health News:Spine Injuries a Common Result of Car Crashes 2Health News:Consumer Advocates Call on Legislature to Support Governor's Ban on Pharmaceutical Gifts to Doctors 2Health News:Consumer Advocates Call on Legislature to Support Governor's Ban on Pharmaceutical Gifts to Doctors 3
... Insulin-like growth factor II (IGF-II) is a ... the liver and is postulated to have mitogenic ... actions of IGF-II are mediated by binding to ... to the Type II IGF receptor, a monomeric ...
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
... proteohormone with a molecular weight of 16 kDa. ... and produced by adipocytes [1,2]. Leptin is thought ... body weight [1-3]. In the human, leptin levels ... women [4]. A relationship between serum leptin levels ...
... known as Anti-Mullerian Inhibiting Substance (AMH), is ... kDa monomers linked by disulfide bridges (1). ... (TGF-?) superfamily which includes TGF-? and the ... members of this superfamily are dimeric glycoproteins, ...
Medicine Products: